Download
00277_2024_Article_5850.pdf 2,47MB
WeightNameValue
1000 Titel
  • Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOP
1000 Autor/in
  1. Kubuschok, Boris |
  2. Otremba, Burkhard |
  3. Welslau, Manfred |
  4. Topaly, Julian |
  5. Wolff, Thomas |
  6. Lenz, Georg |
  7. Grau, Michael |
  8. Bittencourt da Silva, Larissa |
  9. Brückmann, Ines |
  10. Foierl, Tobias |
1000 Verlag Springer Berlin Heidelberg
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-06-20
1000 Erschienen in
1000 Quellenangabe
  • 103(8):3165-3178
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00277-024-05850-5 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11283426/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>Health-related quality of life (HRQoL) data are important indicators of health status in patients with lymphoma. The objective of this analysis was to assess the impact of treatment with Sandoz rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) on HRQoL in treatment-naïve adult patients with diffuse large B-cell lymphoma (DLBCL) included in the prospective, real-world REFLECT study. REFLECT is the first prospective study to assess HRQoL in patients with DLBCL treated with a rituximab biosimilar. HRQoL was assessed via the patient-reported European Organization for Research and Treatment of Cancer Core Quality of Life questionnaire at baseline, mid-treatment (month 3), end of treatment (month 6), and follow-up (months 9 and 12). Subgroup analyses were performed to evaluate the influence of baseline characteristics on HRQoL, and associations between baseline HRQoL and treatment response. HRQoL was assessed in 169 patients. Mean global health status score remained stable from baseline (54.8) to mid-treatment (month 3; 54.7), before steadily improving through to end of treatment (month 6; 61.4), and follow-up month 9 (64.9) and month 12 (68.8). Similar trends were observed across most functional and symptom subscales. Higher cognitive, physical, or role functioning, and less appetite loss, diarrhea, fatigue, or pain at baseline, were all associated with an improved likelihood of reaching a complete versus partial response at the end of treatment. Overall, these findings confirm the HRQoL benefits of R-CHOP therapy in treatment-naïve adult patients with DLBCL, and suggest that baseline HRQoL may be predictive of treatment response.</jats:p>
1000 Sacherschließung
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Cyclophosphamide/therapeutic use [MeSH]
lokal DLBCL
lokal Rituximab/administration
lokal Cyclophosphamide/administration
lokal Rituximab/therapeutic use [MeSH]
lokal Male [MeSH]
lokal Real world
lokal Quality of Life [MeSH]
lokal Doxorubicin/administration
lokal Prednisone/therapeutic use [MeSH]
lokal Biosimilar
lokal Vincristine/administration
lokal Rituximab
lokal Female [MeSH]
lokal Follow-Up Studies [MeSH]
lokal Lymphoma, Large B-Cell, Diffuse/drug therapy [MeSH]
lokal Adult [MeSH]
lokal R-CHOP
lokal Humans [MeSH]
lokal Prospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/administration
lokal Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH]
lokal Prednisone/administration
lokal Quality of life
lokal Research
lokal Germany [MeSH]
lokal Vincristine/therapeutic use [MeSH]
lokal Doxorubicin/therapeutic use [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-5000-2328|https://frl.publisso.de/adhoc/uri/T3RyZW1iYSwgQnVya2hhcmQ=|https://frl.publisso.de/adhoc/uri/V2Vsc2xhdSwgTWFuZnJlZA==|https://orcid.org/0000-0003-2123-4829|https://frl.publisso.de/adhoc/uri/V29sZmYsIFRob21hcw==|https://frl.publisso.de/adhoc/uri/TGVueiwgR2Vvcmc=|https://frl.publisso.de/adhoc/uri/R3JhdSwgTWljaGFlbA==|https://frl.publisso.de/adhoc/uri/Qml0dGVuY291cnQgZGEgU2lsdmEsIExhcmlzc2E=|https://frl.publisso.de/adhoc/uri/QnLDvGNrbWFubiwgSW5lcw==|https://frl.publisso.de/adhoc/uri/Rm9pZXJsLCBUb2JpYXM=
1000 Hinweis
  • DeepGreen-ID: ac682517be64470fa3ddcef3f1a5f772 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Universitätsklinikum Augsburg |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Universitätsklinikum Augsburg |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6517828.rdf
1000 Erstellt am 2025-07-05T07:02:06.747+0200
1000 Erstellt von 322
1000 beschreibt frl:6517828
1000 Zuletzt bearbeitet 2025-08-19T19:39:53.172+0200
1000 Objekt bearb. Tue Aug 19 19:39:53 CEST 2025
1000 Vgl. frl:6517828
1000 Oai Id
  1. oai:frl.publisso.de:frl:6517828 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source